Reuters logo
BRIEF-GSK says asthma drug Nucala (Mepolizumab) meets primary endpoints
March 6, 2017 / 3:27 PM / in 8 months

BRIEF-GSK says asthma drug Nucala (Mepolizumab) meets primary endpoints

March 6 (Reuters) - GlaxoSmithKline Plc:

* Phase IIIB Musca study successfully met all its primary and secondary endpoints

* Patients treated with Nucala (Mepolizumab) achieved clinically and statistically significant improvements in quality of life and lung function versus placebo

* St. Georges respiratory questionnaire improved by 7.7 units from baseline versus. Placebo (p=0.001)

* Lung function (first secondary endpoint), as measured by pre-bronchodilator fev1, increased by 120ml (p=0.001) more than in placebo patients

* Asthma control showed a significant improvement versus. Placebo in Mepolizumab treatment group by 0.40 units (p<0.001)

* Safety profile of Mepolizumab in Musca study was consistent with product label for Nucala Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below